Last reviewed · How we verify
C-BEAM Regimen
C-BEAM is a chemotherapy regimen combining carmustine, etoposide, cytarabine, and melphalan used as conditioning therapy before hematopoietic stem cell transplantation.
C-BEAM is a chemotherapy regimen combining carmustine, etoposide, cytarabine, and melphalan used as conditioning therapy before hematopoietic stem cell transplantation. Used for Conditioning regimen for hematopoietic stem cell transplantation in lymphomas and other hematologic malignancies.
At a glance
| Generic name | C-BEAM Regimen |
|---|---|
| Sponsor | The First Affiliated Hospital with Nanjing Medical University |
| Drug class | Chemotherapy regimen (combination) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
C-BEAM is a myeloablative conditioning regimen designed to eliminate malignant cells and suppress the patient's immune system to allow engraftment of donor stem cells. The combination of four chemotherapy agents targets rapidly dividing cells and provides broad cytotoxic coverage. This regimen is used primarily in lymphoid malignancies to prepare patients for allogeneic or autologous stem cell transplantation.
Approved indications
- Conditioning regimen for hematopoietic stem cell transplantation in lymphomas and other hematologic malignancies
Common side effects
- Myelosuppression
- Mucositis
- Nausea and vomiting
- Infection
- Hepatotoxicity
- Cardiotoxicity
Key clinical trials
- Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS) (PHASE3)
- A Phase III Randomised Control Clinical Trial of Radiotherapy With Radiosensitisation Versus Intravesical Bacillus Calmette-Guerin Therapy for High-risk Non-muscle Invasive Bladder Cancer. (PHASE3)
- MT2022-60: Ph 2 Study of Pembro+ BEAM With ASCT for Relapsed Hodgkin Lymphoma (PHASE2)
- Gene Therapy in Treating Patients With Human Immunodeficiency Virus-Related Lymphoma Receiving Stem Cell Transplant (PHASE1, PHASE2)
- Radiolabeled Monoclonal Antibody Therapy and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With Primary Refractory or Relapsed Hodgkin Lymphoma (PHASE1)
- Yttrium Y 90 Basiliximab and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With Mature T-cell Non-Hodgkin Lymphoma (PHASE1)
- Effect of Laser Acupuncture on Metabolic Syndrome in Obese Postmenopausal Women (NA)
- Hematopoietic Stem Cell Transplantation for Treatment of Multiple Sclerosis in Sweden
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |